Beijing Rongzhiyuan Pharmaceutical Technology

Beijing Rongzhiyuan Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets oncology and metabolic diseases, leveraging its expertise in medicinal chemistry and drug design. Its lead candidate, RZY-001, is a potent and selective inhibitor of Ubiquitin-specific-processing protease 7 (USP7) currently being evaluated in clinical trials for the treatment of advanced solid tumors. Rongzhiyuan aims to address unmet medical needs through the development of first-in-class or best-in-class drugs with improved efficacy and safety profiles.